A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD

Completed · Phase 1

Conditions studied: Age-Related Macular Degeneration

In brief

The safety and comfort of repeated administrations of a topically-administered ophthalmic formulation of MC-1101 will be established through investigator assessments and subject reporting over a 3 day period. Safety assessments will be performed on both normal, healthy subjects as well as those with the signs and symptoms of early non-exudative age-related macular degeneration (dry AMD).

Key facts

Study ID

NCT01013376

Run by

MacuCLEAR, Inc.

People needed

31

Starts

2009-08-01

Expected to finish

2009-08-01

Last updated by the study team

2009-11-13

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Clinical diagnosis of dry AMD or;
• Normal, healthy volunteer

You may not qualify if…

• Uncontrolled systemic disease
• Women who are pregnant, nursing, or planning a pregnancy during the study's duration

Where it is running

• Andover Eye Associates — Andover, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.